These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

955 related articles for article (PubMed ID: 15457463)

  • 1. Involvement of matrix metalloproteinases and their inhibitors in peripheral synovitis and down-regulation by tumor necrosis factor alpha blockade in spondylarthropathy.
    Vandooren B; Kruithof E; Yu DT; Rihl M; Gu J; De Rycke L; Van Den Bosch F; Veys EM; De Keyser F; Baeten D
    Arthritis Rheum; 2004 Sep; 50(9):2942-53. PubMed ID: 15457463
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tumor necrosis factor alpha blockade treatment down-modulates the increased systemic and local expression of Toll-like receptor 2 and Toll-like receptor 4 in spondylarthropathy.
    De Rycke L; Vandooren B; Kruithof E; De Keyser F; Veys EM; Baeten D
    Arthritis Rheum; 2005 Jul; 52(7):2146-58. PubMed ID: 15986373
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunomodulatory effects of etanercept on peripheral joint synovitis in the spondylarthropathies.
    Kruithof E; De Rycke L; Roth J; Mielants H; Van den Bosch F; De Keyser F; Veys EM; Baeten D
    Arthritis Rheum; 2005 Dec; 52(12):3898-909. PubMed ID: 16329106
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association of CD163+ macrophages and local production of soluble CD163 with decreased lymphocyte activation in spondylarthropathy synovitis.
    Baeten D; Møller HJ; Delanghe J; Veys EM; Moestrup SK; De Keyser F
    Arthritis Rheum; 2004 May; 50(5):1611-23. PubMed ID: 15146432
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Turnover of type II collagen and aggrecan in cartilage matrix at the onset of inflammatory arthritis in humans: relationship to mediators of systemic and local inflammation.
    Fraser A; Fearon U; Billinghurst RC; Ionescu M; Reece R; Barwick T; Emery P; Poole AR; Veale DJ
    Arthritis Rheum; 2003 Nov; 48(11):3085-95. PubMed ID: 14613270
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Matrix metalloproteinases and tissue inhibitors of metalloproteinases in synovial fluids of patients with temporomandibular joint osteoarthritis.
    Kanyama M; Kuboki T; Kojima S; Fujisawa T; Hattori T; Takigawa M; Yamashita A
    J Orofac Pain; 2000; 14(1):20-30. PubMed ID: 11203734
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Macrophages expressing the scavenger receptor CD163: a link between immune alterations of the gut and synovial inflammation in spondyloarthropathy.
    Baeten D; Demetter P; Cuvelier CA; Kruithof E; Van Damme N; De Vos M; Veys EM; De Keyser F
    J Pathol; 2002 Mar; 196(3):343-50. PubMed ID: 11857499
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Production of cytokines, vascular endothelial growth factor, matrix metalloproteinases, and tissue inhibitor of metalloproteinases 1 by tenosynovium demonstrates its potential for tendon destruction in rheumatoid arthritis.
    Jain A; Nanchahal J; Troeberg L; Green P; Brennan F
    Arthritis Rheum; 2001 Aug; 44(8):1754-60. PubMed ID: 11508425
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The abundant synovial expression of the RANK/RANKL/Osteoprotegerin system in peripheral spondylarthritis is partially disconnected from inflammation.
    Vandooren B; Cantaert T; Noordenbos T; Tak PP; Baeten D
    Arthritis Rheum; 2008 Mar; 58(3):718-29. PubMed ID: 18311801
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of repeated infliximab therapy on serum matrix metalloproteinases and tissue inhibitors of metalloproteinases in patients with rheumatoid arthritis.
    Klimiuk PA; Sierakowski S; Domyslawska I; Chwiecko J
    J Rheumatol; 2004 Feb; 31(2):238-42. PubMed ID: 14760791
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunomodulatory effects of anti-tumor necrosis factor alpha therapy on synovium in spondylarthropathy: histologic findings in eight patients from an open-label pilot study.
    Baeten D; Kruithof E; Van den Bosch F; Demetter P; Van Damme N; Cuvelier C; De Vos M; Mielants H; Veys EM; De Keyser F
    Arthritis Rheum; 2001 Jan; 44(1):186-95. PubMed ID: 11212159
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tumor necrosis factor alpha drives cadherin 11 expression in rheumatoid inflammation.
    Vandooren B; Cantaert T; ter Borg M; Noordenbos T; Kuhlman R; Gerlag D; Bongartz T; Reedquist K; Tak PP; Baeten D
    Arthritis Rheum; 2008 Oct; 58(10):3051-62. PubMed ID: 18821672
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Active synovial matrix metalloproteinase-2 is associated with radiographic erosions in patients with early synovitis.
    Goldbach-Mansky R; Lee JM; Hoxworth JM; Smith D; Duray P; Schumacher RH; Yarboro CH; Klippel J; Kleiner D; El-Gabalawy HS
    Arthritis Res; 2000; 2(2):145-53. PubMed ID: 11062605
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Quantitation of metalloproteinase gene expression in rheumatoid and psoriatic arthritis synovial tissue distal and proximal to the cartilage-pannus junction.
    Kane D; Jensen LE; Grehan S; Whitehead AS; Bresnihan B; Fitzgerald O
    J Rheumatol; 2004 Jul; 31(7):1274-80. PubMed ID: 15229943
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The effects of interferon-beta treatment of synovial inflammation and expression of metalloproteinases in patients with rheumatoid arthritis.
    Smeets TJ; Dayer JM; Kraan MC; Versendaal J; Chicheportiche R; Breedveld FC; Tak PP
    Arthritis Rheum; 2000 Feb; 43(2):270-4. PubMed ID: 10693865
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Circulating levels of matrix metalloproteinases MMP-3 and MMP-1, tissue inhibitor of metalloproteinases 1 (TIMP-1), and MMP-1/TIMP-1 complex in rheumatic disease. Correlation with clinical activity of rheumatoid arthritis versus other surrogate markers.
    Keyszer G; Lambiri I; Nagel R; Keysser C; Keysser M; Gromnica-Ihle E; Franz J; Burmester GR; Jung K
    J Rheumatol; 1999 Feb; 26(2):251-8. PubMed ID: 9972954
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Absence of a classically activated macrophage cytokine signature in peripheral spondylarthritis, including psoriatic arthritis.
    Vandooren B; Noordenbos T; Ambarus C; Krausz S; Cantaert T; Yeremenko N; Boumans M; Lutter R; Tak PP; Baeten D
    Arthritis Rheum; 2009 Apr; 60(4):966-75. PubMed ID: 19333931
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Correlation between tumor necrosis factor alpha and matrix metalloproteinases levels in serum of patients with rheumatic arthritis].
    Klimiuk PA; Sierakowski S; Chwiećko J
    Pol Merkur Lekarski; 2003 May; 14(83):410-2. PubMed ID: 12939814
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Infiltration of the synovial membrane with macrophage subsets and polymorphonuclear cells reflects global disease activity in spondyloarthropathy.
    Baeten D; Kruithof E; De Rycke L; Boots AM; Mielants H; Veys EM; De Keyser F
    Arthritis Res Ther; 2005; 7(2):R359-69. PubMed ID: 15743484
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Matrix metalloproteinases MMP-3 and MMP-1 levels in sera and synovial fluids in patients with rheumatoid arthritis and osteoarthritis.
    Mahmoud RK; El-Ansary AK; El-Eishi HH; Kamal HM; El-Saeed NH
    Ital J Biochem; 2005; 54(3-4):248-57. PubMed ID: 16688934
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 48.